今日港股回调，创新药再度逆市上涨！港股通创新药ETF（159570）强势大涨近3%，成交额继续爆量，盘中成交近5亿元！上周五成交额再度刷新历史，天 量成交16.49亿元！资金持续乐观，上周累计获资金净流入近2亿元，今日盘中再获净申购4300万份！ 港股通创新药ETF（159570）成分股多数飘红：乐普生物涨超12%，百济神州涨超5%，信达生物涨超3%，晶泰控股涨超2%，康方生物、药明生物、科伦博 泰生物涨超1%。 资金狂涌创新药，港股通创新药ETF（159570）近60日"吸金"近10亿元，融资余额保持历史高位，反映杠杆资金布局意愿！最新规模19.27亿元创上市新 高，1个月实现规模翻倍！ 【机构：医药见底回暖，创新药主线强化】 光大证券认为，医药行情见底回暖，优化集采政策有望稳定资产盈利能力。近期，医药行情整体已显现见底回暖迹象，从2025.1.2~2025.3.27期间，港股创 新药指数上涨26.28%，跑赢恒生科技1.20pp。2025年工作报告提出"优化药品集采政策"，有望优化产业竞争环境，仿制药利润压缩接近尾声，竞争格局趋于 稳定，龙头白马企业凭借技术壁垒与产能优势，盈利能力有望企稳。后集采时代，行 ...

Core Viewpoint - The recent draft proposal from the National Healthcare Security Administration aims to optimize drug procurement policies, which may reshape investor confidence in the pharmaceutical sector and benefit quality generic drug companies [3][4]. Group 1: Market Performance - As of March 31, 2025, the Hang Seng Healthcare Index (HSHCI) increased by 0.02%, with notable gains from companies such as Lepu Biopharma-B (up 4.72%) and Hansoh Pharmaceutical (up 4.66%) [1]. - The Hang Seng Healthcare ETF (513060) rose by 0.84%, with a latest price of 0.48 HKD and a trading volume of 230 million HKD, ranking in the top third among comparable ETFs [1]. Group 2: Policy Changes - The draft proposal includes six main areas of optimization: procurement variety and bidder standards, bidding rules, quantity rules, implementation measures, quality assessment, and information transparency [3]. - The adjustments aim to eliminate the previous low-price bidding rule, prevent malicious low bidding by companies, and ensure stable supply through a "stockout" mechanism [3]. Group 3: Investment Insights - The recent draft is expected to restore investor confidence in hospital medication, potentially benefiting quality generic drug companies and those with significant market space [4]. - The Hang Seng Healthcare ETF has seen a growth of 270 million HKD in scale over the past six months, with a financing buy-in amount of 420 million HKD and a financing balance of 576 million HKD [4]. Group 4: Performance Metrics - Since its inception, the Hang Seng Healthcare ETF has achieved a maximum monthly return of 28.34% and an average monthly return of 7.00% [4]. - As of March 28, 2025, the ETF's maximum drawdown this year was 6.06%, the smallest among comparable funds, with a management fee of 0.50% and a custody fee of 0.15% [5]. - The ETF's tracking error was 0.032%, the highest tracking precision among comparable funds, and its latest price-to-earnings ratio (PE-TTM) was 25.15, indicating a valuation below 97.83% of the past year [5]. Group 5: Top Holdings - The top ten weighted stocks in the Hang Seng Healthcare Index account for 55.69% of the index, including WuXi Biologics (02269) and BeiGene (06160) [5].

Core Insights - Hansoh Pharmaceutical reported a total revenue of approximately 12.261 billion RMB for 2024, representing a year-on-year growth of about 21.3%, and a net profit attributable to shareholders of 4.372 billion RMB, up 33.4% year-on-year [1] - The proportion of innovative drugs in total revenue increased significantly from less than 20% at the time of the company's Hong Kong listing to 77.3% in 2024, highlighting the successful transition to an innovation-driven pharmaceutical company [1][5] - The company achieved revenue of 9.477 billion RMB from innovative drugs and collaborative products, marking a year-on-year increase of 38.1% [1] Revenue Breakdown - In 2024, revenue from various therapeutic areas included approximately 8.122 billion RMB from oncology, 1.464 billion RMB from anti-infection, 1.379 billion RMB from central nervous system disorders, and 1.296 billion RMB from metabolic and other diseases, accounting for 66.2%, 11.9%, 11.3%, and 10.6% of total revenue respectively [1] R&D Investment - The company invested 2.702 billion RMB in R&D, which accounted for 22% of total revenue, focusing on major disease areas such as oncology, central nervous system disorders, metabolism, and autoimmune diseases [2] - Key products in development include the lung cancer treatment Amelot, which has three indications entering NDA stage, and other drugs like HS-20094 and HS-10374 progressing to Phase III clinical trials [2] Business Development (BD) Cooperation - In 2024, revenue from BD cooperation reached 1.573 billion RMB, including a 185 million USD upfront payment from GSK for HS-20093 [4] - The company secured a global exclusive license for an oral GLP-1 small molecule from Merck, receiving an upfront payment of 112 million USD and potential milestone payments of up to 1.9 billion USD [4] - Collaborations with international pharmaceutical companies like GSK and Merck are aimed at accelerating global market expansion [4] Strategic Direction - The company aims to continue its transformation from generics to innovative drugs, leveraging R&D and international strategies while enhancing BD cooperation to optimize its global market presence [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company has shown significant results in its innovative transformation, with internationalization accelerating. The revenue from innovative products is growing rapidly, and the core product, Amivantamab, is expected to reach peak sales of 8 billion yuan. The company continues to benefit from overseas licensing agreements, contributing positively to its performance [5][8]. Financial Performance Summary - For the fiscal year 2024, the company reported total revenue of 12.261 billion yuan, a year-on-year increase of 21.3%. Product sales revenue was 10.688 billion yuan, while collaboration and licensing income was 1.573 billion yuan. The net profit attributable to shareholders was 4.372 billion yuan, reflecting a year-on-year growth of 33.4% [6]. - The company’s operating income and profit both achieved double-digit year-on-year growth, with product sales revenue increasing by 13.65% compared to 9.403 billion yuan in 2023 [6]. Revenue and Profit Forecast - The company’s revenue forecast for 2025 is 13.604 billion yuan, with a projected growth rate of 10.95%. The net profit attributable to shareholders is expected to be 4.421 billion yuan, with a growth rate of 1.14% [7]. - The earnings per share (EPS) for 2025 is projected to be 0.74 yuan, with a return on equity (ROE) of 13.4% [7]. Innovative Product Performance - The revenue from innovative drugs grew by 38.1% year-on-year, reaching 9.477 billion yuan in 2024, accounting for 77.3% of total revenue. The sales of innovative drugs, excluding licensing income, are expected to reach approximately 8 billion yuan, reflecting a year-on-year increase of 28.5% [8]. - The company has a rich pipeline of innovative products, with several expected to be approved soon, providing long-term support for its innovative transformation [8]. Market Position and Future Outlook - The company is well-positioned for future growth, with expectations that the proportion of revenue from innovative drugs will exceed 80% by 2025. The sales of Amivantamab are projected to reach 6 billion yuan, with an upward revision of peak sales to 8 billion yuan [8].

Core Viewpoint - The recent exclusive licensing agreement between Novo Nordisk and a Chinese innovative drug company for the weight loss drug UBT251, valued at up to $2 billion, highlights the global recognition of China's innovative pharmaceutical capabilities [1] Group 1: Market Performance - The Hong Kong innovative drug ETF (159567) rose by 0.44% today, marking two consecutive days of net capital inflow [1] - The average daily trading volume of the Hong Kong innovative drug ETF over the past month was 189 million yuan, ranking first in liquidity among indices [1] - The Hong Kong stock market saw a slight rebound on March 26, with the innovative drug sector continuing to recover amid increased market attention on domestic innovative drug companies [1] Group 2: Company Performance - Major companies in the Hong Kong innovative drug index showed positive performance, with three companies, including 3SBio, rising over 10%, and several others, such as WuXi AppTec and Kintor Pharmaceutical, increasing by over 4% [2] - Recent financial reports from leading drug companies indicate a positive trend in fundamentals, with WuXi AppTec achieving a record high quarterly revenue in Q4 2024 and a 47% year-on-year increase in order size [3] - Hansoh Pharmaceutical reported a 33.4% year-on-year increase in net profit for 2024, with innovative drug revenue accounting for 77.3% of total revenue [3] Group 3: Industry Trends - The share of China's pharmaceutical licensing transactions valued over $5 million has increased from less than 5% in 2020 to approximately 30% in 2024 [3] - In the first two months of 2025, there were 16 licensing projects for Chinese innovative drugs, accounting for nearly 50% of global transaction value [3] - The innovative drug sector in Hong Kong is expected to have greater valuation expansion potential compared to A-shares, driven by higher R&D expenditure and overseas revenue ratios [4]

Investment Rating - The report maintains an "Outperform" rating for Sino Biopharmaceutical [2][11][17] Core Insights - The company achieved revenue of CNY 28.9 billion in FY24, reflecting a year-on-year growth of 10.2%, with a gross profit margin of 81.5% [3][14] - Innovative products are expected to drive double-digit revenue growth in FY25, particularly in oncology and surgery/analgesia segments [4][15] - The company plans to launch seven innovative products in FY25, including key candidates such as TQB3616 and Meloxicam [5][16] Financial Performance - FY24 revenue was CNY 28.9 billion, with a net profit of CNY 3.5 billion, marking a 50.1% increase year-on-year [3][14] - R&D expenses increased by 15.6% to CNY 5.1 billion, representing 17.6% of total revenue [3][14] - The company expects revenue to reach CNY 32.4 billion in FY25, a growth of 12.3% year-on-year [6][16] Product Segments - Revenue from innovative drugs reached CNY 12.1 billion, up 22% year-on-year, while generics contributed CNY 16.8 billion, growing 3% [4][15] - The oncology segment generated CNY 10.7 billion, driven by strong sales of key products [18] - The surgery/analgesia segment saw a revenue increase of 19% to CNY 4.5 billion, supported by the sales of Flurbiprofen Cataplasms [18] Future Outlook - The company anticipates significant contributions from new product launches and clinical data readouts in 2025 [5][16] - Management expects the liver diseases segment to introduce one innovative drug and five biosimilars/generics between 2025 and 2027 [18] - The report projects a target price of HKD 5.52 for the stock, based on a P/E ratio of 25.2x for 2025 [6][17]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 25.00 [6][8][17] Core Insights - The company's revenue for 2024 is expected to increase by 21.3% to RMB 12.26 billion, with a net profit growth of 33.4%, exceeding expectations [1][6] - The oncology drug segment is projected to contribute 61.2% of the total product sales revenue in 2024, driven by strong performance from the core product Amelot, which is expected to see sales growth of 19.9% [2] - The company has established a partnership with Merck for the development and commercialization of a GLP-1 receptor agonist, which is expected to enhance its capabilities in the metabolic field [4] - The company is currently developing 40 innovative drugs, with several in late-stage clinical trials, indicating a promising pipeline for future growth [5] Financial Summary - The company's revenue is projected to grow from RMB 10.10 billion in 2023 to RMB 12.26 billion in 2024, with a compound annual growth rate (CAGR) of 21.3% [7][14] - Shareholder net profit is expected to rise from RMB 3.28 billion in 2023 to RMB 4.37 billion in 2024, reflecting a growth rate of 33.4% [7][14] - The gross margin is anticipated to improve by 1.2 percentage points, while sales and administrative expenses as a percentage of product sales revenue are expected to decrease [1][7] Product and Market Developments - The oncology drug business is expected to grow from approximately RMB 6.55 billion in 2024 to RMB 10.97 billion by 2027, with a CAGR of 18.8% [2] - The anti-infection drug revenue is projected to increase by 15.0% to RMB 1.46 billion in 2024, primarily driven by the strong sales of the hepatitis drug Hengmu [3] - The company has received multiple recommendations for its products in clinical guidelines, which is expected to support future sales growth [3]

Investment Rating - The report maintains an "Outperform" rating for Sino Biopharmaceutical [2][11][17] Core Insights - The company achieved revenue of CNY 28.9 billion in FY24, reflecting a year-on-year growth of 10.2% with a gross profit margin of 81.5% [3][14] - Innovative products are expected to drive double-digit revenue growth in FY25, particularly in oncology and surgery/analgesia segments [4][15] - The company plans to launch seven innovative products in FY25, including key candidates such as TQB3616 and Meloxicam [5][16] Financial Performance - FY24 revenue was CNY 28.9 billion, with a net profit of CNY 3.5 billion, marking a 50.1% increase year-on-year [3][14] - R&D expenses increased by 15.6% to CNY 5.1 billion, representing 17.6% of total revenue [3][14] - The company expects revenue to reach CNY 32.4 billion in FY25, a growth of 12.3% year-on-year [6][16] Segment Performance - Revenue from innovative drugs reached CNY 12.1 billion, up 22% year-on-year, while generics contributed CNY 16.8 billion, growing 3% [4][15] - The oncology segment generated CNY 10.7 billion, driven by strong sales of key products [18] - The surgery/analgesia segment saw a revenue increase of 19% to CNY 4.5 billion, primarily due to the sales of Flurbiprofen Cataplasms [18] Valuation - The target price is adjusted to HKD 5.52, based on a 2025E PE of 25.2x [6][17] - The report reflects a slight adjustment in revenue forecasts for 2025-26 due to uncertainties in biosimilar revenue growth [6][16]

Core Insights - Jiangsu Hengrui Medicine Co., Ltd. has signed a collaboration agreement with Merck to license its oral small molecule drug targeting lipoprotein(a) (HRS-5346) for a payment of $200 million upfront [3][4] - The agreement allows Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 outside Greater China, with potential milestone payments reaching up to $1.77 billion and additional sales royalties based on performance [3][4] - HRS-5346 is currently undergoing Phase II clinical trials in China and targets elevated Lp(a) levels, which are linked to cardiovascular diseases [4][5] Financial Implications - The total potential revenue for Hengrui from this collaboration could approach $2 billion, including upfront payments, milestone payments, and sales royalties [3][4] - Hengrui has previously engaged in 12 licensing deals since 2018, totaling approximately $12 billion, with upfront payments around $400 million [4] Strategic Importance - This partnership is expected to enhance Hengrui's international market presence and improve its innovative brand and overseas performance [5] - The collaboration aligns with Hengrui's strategy of balancing in-house development with external partnerships to accelerate the global reach of its innovative products [5]

创下新高！一款国产减肥药卖了20亿美元 当下最火热的降糖减重领域又现重磅交易。 3月24日晚间，国内药企联邦制药宣布与跨国药企诺和诺德签订独家许可协议。后者将获得前者三 靶点GLP-1药物UBT251在海外的开发、制造和商业化权益。 而在"主战场"GLP-1药物上，诺和诺德和礼来两大龙头缠斗已久，两者分别推出了司美格鲁肽、替 尔泊肽两大明星产品，用于2型糖尿病和减重。 这也不断推高了该领域的竞争难度，并使GLP-1药物开发从日制剂做到周制剂，从注射到口服，从 单靶点到多靶点产品，追求降糖减重效果的同时，平衡药物安全性、耐受性，提高患者依从性，并探索 更多方面的临床获益。 2024年，司美格鲁肽、替尔泊肽全球销售额分别为293亿美元、165亿美元，前者直逼当年全球销售 额"药王"的水平。但在后续管线上，诺和诺德此时显得较为弱势。 根据协议，联邦制药将有资格获得2亿美元预付款、最高18亿美元的潜在里程碑付款，及相应分层 销售提成。 不过3月25日开盘，联邦制药股价一路大跌，收盘价报14.680港元/股，跌11.78%，当下市值267亿 港元。 消息面上，除前述交易外，联邦制药还公布了2024年业绩。当期，公司营收 ...